Company Description

Sling Therapeutics is a clinical-stage biopharmaceutical company focused on the late-stage advancement of an oral small molecule therapy for the treatment of thyroid eye disease (TED). Linsitinib, an IGF-1R (insulin-like growth factor 1 receptor) inhibitor, is designed to provide TED patients with an effective, convenient oral treatment option while reducing the treatment burden on patients, physicians and the healthcare system.